Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial

异环磷酰胺 医学 阿霉素 外科 软组织肉瘤 内科学 化疗 肿瘤科 肉瘤 软组织 病理 顺铂
作者
Ian Robert Judson,Jaap Verweij,Hans A. J. Gelderblom,Jörg Thomas Hartmann,Patrick Schöffski,Jean‐Yves Blay,Jan Martijn Kerst,Jozef Šufliarský,Jeremy Whelan,Peter Hohenberger,Anders Krarup‐Hansen,Thierry Alcindor,Sandrine I. Marreaud,Saskia Litière,C. Hermans,Cyril Fisher,Pancras C.W. Hogendoorn,Angelo Paolo Dei Tos,Winette T.A. van der Graaf
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:15 (4): 415-423 被引量:1203
标识
DOI:10.1016/s1470-2045(14)70063-4
摘要

Effective targeted treatment is unavailable for most sarcomas and doxorubicin and ifosfamide-which have been used to treat soft-tissue sarcoma for more than 30 years-still have an important role. Whether doxorubicin alone or the combination of doxorubicin and ifosfamide should be used routinely is still controversial. We assessed whether dose intensification of doxorubicin with ifosfamide improves survival of patients with advanced soft-tissue sarcoma compared with doxorubicin alone.We did this phase 3 randomised controlled trial (EORTC 62012) at 38 hospitals in ten countries. We included patients with locally advanced, unresectable, or metastatic high-grade soft-tissue sarcoma, age 18-60 years with a WHO performance status of 0 or 1. They were randomly assigned (1:1) by the minimisation method to either doxorubicin (75 mg/m(2) by intravenous bolus on day 1 or 72 h continuous intravenous infusion) or intensified doxorubicin (75 mg/m(2); 25 mg/m(2) per day, days 1-3) plus ifosfamide (10 g/m(2) over 4 days with mesna and pegfilgrastim) as first-line treatment. Randomisation was stratified by centre, performance status (0 vs 1), age (<50 vs ≥50 years), presence of liver metastases, and histopathological grade (2 vs 3). Patients were treated every 3 weeks till progression or unacceptable toxic effects for up to six cycles. The primary endpoint was overall survival in the intention-to-treat population. The trial is registered with ClinicalTrials.gov, number NCT00061984.Between April 30, 2003, and May 25, 2010, 228 patients were randomly assigned to receive doxorubicin and 227 to receive doxorubicin and ifosfamide. Median follow-up was 56 months (IQR 31-77) in the doxorubicin only group and 59 months (36-72) in the combination group. There was no significant difference in overall survival between groups (median overall survival 12·8 months [95·5% CI 10·5-14·3] in the doxorubicin group vs 14·3 months [12·5-16·5] in the doxorubicin and ifosfamide group; hazard ratio [HR] 0·83 [95·5% CI 0·67-1·03]; stratified log-rank test p=0·076). Median progression-free survival was significantly higher for the doxorubicin and ifosfamide group (7·4 months [95% CI 6·6-8·3]) than for the doxorubicin group (4·6 months [2·9-5·6]; HR 0·74 [95% CI 0·60-0·90], stratified log-rank test p=0·003). More patients in the doxorubicin and ifosfamide group than in the doxorubicin group had an overall response (60 [26%] of 227 patients vs 31 [14%] of 228; p<0·0006). The most common grade 3 and 4 toxic effects-which were all more common with doxorubicin and ifosfamide than with doxorubicin alone-were leucopenia (97 [43%] of 224 patients vs 40 [18%] of 223 patients), neutropenia (93 [42%] vs 83 [37%]), febrile neutropenia (103 (46%) vs 30 [13%]), anaemia (78 [35%] vs 10 [5%]), and thrombocytopenia (75 [33%]) vs one [<1%]).Our results do not support the use of intensified doxorubicin and ifosfamide for palliation of advanced soft-tissue sarcoma unless the specific goal is tumour shrinkage. These findings should help individualise the care of patients with this disease.Cancer Research UK, EORTC Charitable Trust, UK NHS, Canadian Cancer Society Research Institute, Amgen.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
刚刚
刚刚
刚刚
3475发布了新的文献求助10
1秒前
树枝完成签到 ,获得积分10
1秒前
cjr完成签到,获得积分10
2秒前
共享精神的应助被无糖可乐采纳,获得10
2秒前
无限水杯发布了新的文献求助10
2秒前
Vexolve完成签到 ,获得积分10
2秒前
No发布了新的文献求助10
3秒前
隐形曼青的应助被斗战圣牛采纳,获得10
3秒前
3秒前
追寻如萱发布了新的文献求助10
4秒前
4秒前
4秒前
小鱼发布了新的文献求助10
5秒前
qin202569发布了新的文献求助10
5秒前
5秒前
CarryLJR的应助被慧子采纳,获得10
5秒前
调皮子默发布了新的文献求助20
6秒前
6秒前
一口辰发布了新的文献求助20
6秒前
GPTea的应助被聪明甜桃采纳,获得20
6秒前
宋宋不迷糊完成签到 ,获得积分10
7秒前
晚风发布了新的文献求助10
8秒前
DW的应助被小破饼干采纳,获得10
8秒前
9秒前
9秒前
Maestro_S的应助被tomatoGG采纳,获得10
9秒前
Lumen完成签到,获得积分10
10秒前
东方元语发布了新的文献求助10
10秒前
11秒前
wangbw发布了新的文献求助10
11秒前
我爱行楷完成签到,获得积分10
11秒前
百变怪完成签到 ,获得积分10
11秒前
11秒前
nikola发布了新的文献求助10
12秒前
大个的应助被面包人采纳,获得10
12秒前
13秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
Grapes 1000
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8178807
求助须知:如何正确求助?哪些是违规求助? 9569558
关于积分的说明 21805222
捐赠科研通 7773974
什么是DOI,文献DOI怎么找? 3432933
关于科研通互助平台的介绍 2556873
邀请新用户注册赠送积分活动 2478593